Legal & General Group Plc Has $113,000 Stake in TG Therapeutics, Inc. (TGTX)

Legal & General Group Plc raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 4.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,801 shares of the biopharmaceutical company’s stock after buying an additional 384 shares during the period. Legal & General Group Plc’s holdings in TG Therapeutics were worth $113,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the company. Bank of Montreal Can acquired a new stake in TG Therapeutics during the first quarter valued at about $443,000. Ameriprise Financial Inc. acquired a new stake in TG Therapeutics during the first quarter valued at about $1,291,000. North Star Investment Management Corp. increased its stake in TG Therapeutics by 110.0% in the first quarter. North Star Investment Management Corp. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 11,000 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in TG Therapeutics during the first quarter valued at about $811,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in shares of TG Therapeutics during the first quarter worth $928,000. Institutional investors own 46.53% of the company’s stock.

Shares of TG Therapeutics, Inc. (NASDAQ TGTX) traded down 1.36% on Friday, reaching $10.85. The company had a trading volume of 889,366 shares. The company’s 50-day moving average is $10.91 and its 200 day moving average is $10.23. The firm’s market capitalization is $676.06 million. TG Therapeutics, Inc. has a 12 month low of $4.10 and a 12 month high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. Equities analysts forecast that TG Therapeutics, Inc. will post ($1.84) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “[[title]]” was first reported by [[site]] and is the property of of [[site]]. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at [[permalink]].

A number of equities research analysts have recently weighed in on TGTX shares. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a report on Monday, May 1st. Jefferies Group LLC started coverage on TG Therapeutics in a report on Tuesday, April 25th. They issued a “buy” rating and a $23.00 price target for the company. Raymond James Financial, Inc. reiterated a “buy” rating on shares of TG Therapeutics in a report on Friday, April 21st. Zacks Investment Research upgraded TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Thursday, July 13th. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $23.67.

In related news, CFO Sean A. Power sold 59,976 shares of the firm’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $11.09, for a total transaction of $665,133.84. Following the completion of the sale, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at approximately $5,295,075.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 16.70% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.